GLOBALKRATOM.ORG · Evidence-based CDC report for clinicians, journalists, and families
Whole‑Leaf Kratom · Not Just Synthetics

Banning 7‑OH Alone Won't Protect Families.
Natural Kratom Causes Real Harm.

This library compiles peer‑reviewed evidence, FDA reports, and CDC case studies documenting the dangers of unregulated whole‑leaf kratom – dependence, withdrawal, liver injury, cardiac arrest, and deaths.

MISSION

We advocate for evidence‑based policy that protects public health, informs lawmakers, and prevents harm from unregulated kratom – including natural whole leaf products, not just high‑potency extracts.

Kratom leaf - whole leaf harms
🍃

Natural Leaf vs Extracts:
What Policymakers Should Know

Even before high‑potency 7‑OH extracts emerged, whole‑leaf kratom was associated with severe outcomes, contamination, and healthcare burden. Understanding the full market matters for effective regulation.

LEARN MORE →
South Carolina State Representative Rutherford
⚖️
"The FDA didn't ban it!"
– South Carolina State Representative Rutherford

Despite decades of documented harms, whole‑leaf kratom remains unregulated. Learn why federal action has stalled – and what can still be done.

Learn More →
Kratom export containers and international shipping
📄
"Following the Kratom Supply Chain"
– Global Kratom Policy Review

An evidence-based introduction to international kratom shipping records for lawmakers. Bills of lading, HTS codes, FDA Import Alert 54-15, and public records.

Explore the Series →
KEY PUBLIC HEALTH INDICATORS

Federal and poison-center surveillance signals

Data from national systems tracking kratom-related harms, exposures, and adverse events.
CDC
CDC SUDORS
1,151
Kratom/mitragynine detected in overdose deaths in 2023 across participating jurisdictions.
2020–2024 range: 866 to 1,151 annual detections
America's Poison Centers
AMERICA'S POISON CENTERS
14,449
Poison center exposure reports involving kratom from 2011–2023.
National Poison Data System surveillance
FDA
FDA FAERS
1,470
FAERS adverse-event reports associated with kratom/mitragynine.
Includes 722 death outcomes and 370 hospitalizations

The Issues

Scientific evidence shows significant public health risks from whole‑leaf kratom and its alkaloids.

Liver injury
●

Liver Injury

Cases of cholestatic injury, liver failure, and transplant linked to kratom use. Recovery often occurs after cessation (NIH LiverTox).

Learn More →
Pregnancy risk
⚕

Pregnancy & Neonatal Risk

Evidence of neonatal withdrawal, limited safety data, and potential harm to developing infants.

Learn More →
Youth exposure
👥

Youth & College Exposure

Increasing use among adolescents and college students fueled by aggressive marketing and easy access.

Learn More →
Contamination
⚗

Product Contamination

Heavy metals, microbes, pesticides, adulterants, and variable potency found in many products (FDA lab data).

Learn More →
Lawmaker policy resources
🏛

For Lawmakers:
Better Policy Saves Lives

Outdated laws and lack of enforcement leave families vulnerable. We provide the data, documents, and expert analysis needed to protect communities. (State Laws Summary)

Resources for Lawmakers →
University of Florida kratom patent investigation examining a proposed 40 mg mitragynine cap, enhanced absorption technology, and undisclosed patent interests
Scientific Ethics · University of Florida Patent · Regulatory Conflicts

40 mg of Mitragynine: The Policy Proposal, the Patent, and the Missing Disclosure

Three University of Florida researchers recommended a 40 mg mitragynine serving limit while holding inventor status on a patent application for technology designed to increase mitragynine absorption. Christopher McCurdy, Abhisheak Sharma, and Erin Berthold appear on both the October 2026 regulatory policy paper and the university's patent application, which includes formulations containing up to 40 mg of mitragynine. Yet the published conflict-of-interest statement makes no mention of the patent. Why does that matter? A milligram ceiling limits the amount of drug in a serving, not necessarily how much reaches the bloodstream. Enhanced-absorption technology could offer a competitive advantage if permitted under the proposed rules. Even American Kratom Association lobbyist Mac Haddow questioned the missing disclosure. This investigation examines the original patent, the proposed regulatory limits, the potential commercial implications, and the questions the researchers and their journal have yet to answer.

November 8, 2026
Shaman Botanicals FDA notification revealing that 7-hydroxymitragynine is manufactured from kratom
FDA Records · 7-OH Manufacturing · Kratom Supply Chain

In a Manufacturer's Own Words: 7-OH Is Made From Kratom

The kratom industry urges lawmakers to distinguish natural kratom from chemically modified 7-OH products. But a manufacturer's own FDA submission exposes a critical connection. In December 2025, FDA explicitly acknowledged that Shaman Botanicals' 7-OH was manufactured from kratom and demanded detailed records identifying its raw materials and manufacturing process. The company's subsequent disclosures were heavily redacted. This investigation examines the original federal filing, the botanical supply chain behind concentrated 7-OH products, and the manufacturing relationship too often omitted from industry lobbying arguments. Read the documents lawmakers should be asking about.

November 6, 2026
COA fraud investigation: falsified laboratory reports, manipulated THC testing, contaminated cannabis products, and kratom labeling discrepancies
Laboratory Fraud · Kratom & THC · Regulatory Investigations

COA Fraud Exposed: When Laboratory Certificates Cannot Be Trusted

A Certificate of Analysis is supposed to assure consumers that a product has been tested. But what happens when the certificate is forged, the laboratory manipulates its results, or the product bears little resemblance to what was tested? From falsified THC potency reports and concealed contaminants to troubling discrepancies in kratom labeling, this investigation examines nine documented cases and additional scientific findings. Explore regulatory enforcement records, laboratory investigations, and original sources exposing why a COA is not, by itself, proof of product safety.

October 26, 2026
OPMS kratom wrongful-death lawsuit: federal court records, sworn testimony, corporate evidence, and expert reports
Federal Litigation · Kratom Safety · Court Evidence

OPMS Kratom: Inside the Federal Court Records

A Louisiana wrongful-death lawsuit has produced an extraordinary collection of evidence involving botanical kratom, including corporate records, product warnings, autopsy findings, sworn testimony, and competing scientific opinions. Explore 280 original PACER PDFs spanning 4,819 pages, with ten detailed investigations and a full-text search engine that takes readers directly to the evidence. The allegations are contested, but the court records are available for anyone to examine.

October 25, 2026
Physicians who recommend or prescribe kratom for medical treatment: public evidence registry
Medical Evidence · Physician Recommendations

Physicians Who Recommend or Prescribe Kratom: The Evidence Registry

Kratom is promoted for chronic pain, anxiety, opioid withdrawal, and numerous other medical conditions. But which licensed physicians publicly recommend or prescribe it as a treatment? This registry is reserved for documented physician endorsements supported by verifiable evidence. The first entry awaits a name.

October 24, 2026
U.S. Patent US20230250098A1 documents extraction of natural kratom alkaloids and development of opioid-active chemical derivatives
Patent Research · Kratom-Derived Opioids

From Kratom Leaf to New Opioid Compounds: The Patent Evidence

A U.S. patent documents researchers extracting four alkaloids from commercially purchased kratom powder, developing new chemical derivatives, and demonstrating opioid-receptor activity. The research raises a question for lawmakers: What happens when the natural leaf becomes the starting material for the next generation of opioid compounds?

October 16, 2026
End Gas Station Heroin Act investigation into botanical kratom exemptions and documented harms before 2024
Federal Legislation · Kratom Policy

End Gas Station Heroin. But Leave Gas Station Kratom?

Congress proposes targeting potent kratom-derived compounds while leaving botanical kratom outside the bill's prohibitions. But seizures, comas, respiratory depression and deaths were documented long before 2024. We examine the bill's loopholes, the historical evidence and the American Kratom Association's support.

October 12, 2026
2026 controlled human study examining kratom abuse potential, drug effects, and adverse events
Clinical Research · Human Abuse Potential

116 Human Subjects. What Did the Kratom Abuse Study Find?

A 2026 placebo-controlled human study found dose-related psychoactive effects and abuse-related adverse events following dried kratom leaf consumption. We examine the findings, concerning effects, study limitations, and the involvement of American Kratom Association consultant Jack Henningfield.

October 10, 2026
October 9, 2026 DEA and HHS revised scheduling announcement for 7-hydroxymitragynine and mitragynine pseudoindoxyl
Federal Policy · DEA / HHS

Washington Changed the Thresholds. It Left Kratom Leaf Alone.

The October 9 announcement introduces new concentration and alkaloid-ratio thresholds for 7-OH and mitragynine pseudoindoxyl. But the revised approach leaves botanical kratom and its mitragynine supply outside these proposed controls. The finished molecules face scheduling while their upstream source remains available.

October 9, 2026
U.S. patent showing mitragynine analog chemistry beginning with mitragynine derived from kratom leaf
Investigation · Kratom Chemistry

Ban One Molecule. What Happens When Chemists Make the Next One?

A U.S. patent shows mitragynine extracted from kratom leaf can serve as the scaffold for dozens of chemical modifications, including compounds with altered opioid-receptor activity. States can name analogs in legislation, but identifying an unknown derivative in a retail product requires actually knowing what to test for.

October 7, 2026
Comparison of kratom, 7-hydroxymitragynine and mitragynine pseudoindoxyl toxicity using PubMed, FDA adverse-event and Poison Center data
Evidence · Toxicology

Kratom vs. 7-OH vs. Pseudoindoxyl: Different Toxicities, Same Family

PubMed case reports, FDA adverse-event data and Poison Center surveillance show different toxicity profiles. Kratom has published reports involving seizures, liver injury, rhabdomyolysis and major cardiac events; concentrated 7-OH is producing serious opioid-like and cardiac toxicity; and the human evidence on mitragynine pseudoindoxyl is only beginning to emerge.

October 4, 2026
Investigation tracing high-potency 7-OH and mitragynine pseudoindoxyl products back to raw kratom leaf
Investigation · Kratom Supply Chain

Follow the Molecule Back: Where High-Potency Kratom Products Begin

7-OH and pseudoindoxyl may look nothing like kratom leaf. But product testing, patents, UN drug monitoring and commercial manufacturing evidence trace the chemistry upstream: raw kratom supplies mitragynine, the starting material manufacturers can chemically transform into increasingly potent products.

October 3, 2026
FDA kratom import refusals, accepted entries and U.S. bill of lading investigation
Investigation · FDA Imports

FDA Has Refused Kratom 1,177 Times. So Why Is It Still Letting It In?

FDA records show 1,177 kratom refusals—yet since 2020, 180 kratom entry lines categorized as Human Food were allowed to proceed or released. Twenty-four were detained first, then released. We compared FDA’s own data with U.S. bills of lading to examine what is getting through.

September 30, 2026
2026 NACS Show and kratom companies marketing to the convenience-store industry
Industry · Retail Pipeline

The Gas Station Pipeline

Kratom itself cannot be sold, sampled, distributed or openly possessed at the 2026 NACS Show. Its manufacturers, however, can exhibit and market to the convenience-store industry. We identified the kratom companies headed to Las Vegas—and examined the pipeline from manufacturer to gas-station shelf.

September 28, 2026
f
Arizona lawsuit against Botanic Tonics over Feel Free kratom marketing
Consumer Protection · Court Records

Arizona Sues Botanic Tonics

Arizona alleges the founder tested Feel Free on himself at “abusive levels”—about six bottles a day until he “felt toxic”—before the product was mass-marketed as wellness, energy and an alcohol alternative. Now the State is putting what the company allegedly knew, how it marketed the product, and how it encouraged repeat purchases before a court.

September 23, 2026
The Work-Free Drug Place workplace safety and kratom testing article
Workplace Safety · Policy

Welcome to the Work-Free Drug Place

Police officers, firefighters, nurses, truck drivers and equipment operators described kratom use while working in safety-sensitive roles. Meanwhile, court-submitted science discusses seizures, psychosis, sedation, hallucinations and impaired cognition—and standard workplace testing may never look for it.

September 17, 2026
The Ohio Files state kratom court record for lawmakers
Court Records · Policy

The Ohio Files: What Botanic Tonics Put on the State Court Record

Under oath and in its own filings: mitragynine as a partial mu-opioid agonist, admitted addiction potential, extract concentration risks, finished-product uncertainty, and 1,600+ retail outlets. Read the record—not the talking points.

September 12, 2026
The Utah Files federal kratom court record for lawmakers
Court Records · Policy

The Utah Files: What the Kratom Industry Put on the Federal Court Record

Under oath and in its own filings: MP in natural leaf, acknowledged kratom risks, disputed safety claims, clinical-study limits, and product-quality evidence. Read the record—not the talking points.

September 8, 2026
Policy news
Policy

States Move to Protect Families as Kratom-Related Harms Rise

May 8, 2026
Reddit user reports
User Reports

Does Pure Leaf Kratom Get You High? A Review of Reddit User Reports

June 6, 2026
FDA clinical trial
Clinical Trial

Does Pure Leaf Kratom Get You High? Part II – The FDA-Sponsored Human Trial

June 29, 2026
Florida 7-OH
Regulation

Florida Raises 7‑OH Limit 2.5× Despite Declaring "Imminent Hazard"

June 25, 2026
Pinney's Plan
Policy Analysis

Pinney's Plan. DEA's Policy. – How an Industry-Linked Strategy Became Federal Policy

July 9, 2026
Whole-leaf kratom dependence analysis
Policy Analysis

Connecticut Consumer Accounts Reveal Severe Whole‑Leaf Kratom Dependence

July 17, 2026
Following the kratom supply chain investigation
Supply Chain

Following the Kratom Supply Chain: What One Bill of Lading Reveals

July 28, 2026
Botanic Tonics investigation by Senate Finance Committee
Investigations

Botanic Tonics Investigation: FDA Safety Claim Under Senate Scrutiny

August 3, 2026
The 24 Million Kratom Users Mirage - methodological critique
Methodology

The "24 Million Kratom Users" Mirage

August 26, 2026
Kratom ban analysis icon
Policy Analysis

They Banned Kratom. The Disaster Never Came.

August 29, 2026
👥
We are mothers, families, clinicians, and concerned citizens united to end preventable harm.Whole‑leaf kratom is not a harmless botanical. Real oversight, testing, and enforcement can save lives.